Feasibility study of the immunogenicity and safety of a novel DTPw/Hib (PRP-T) Brazilian combination compared to a licensed vaccine in healthy children at 2, 4, and 6 months of age
Vaccination of infants with conjugated Haemophilus influenzae type b (Hib) vaccines has been proven to reduce Hib meningitis by 95% and pneumoniae by 20%. The routine use of Hib vaccine is facilitated by the introduction of combination vaccines into the EPI (Expanded Plan of Immunization). The objec...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Brasileira de Medicina Tropical (SBMT)
2003-06-01
|
| Series: | Revista da Sociedade Brasileira de Medicina Tropical |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822003000300002&tlng=en |
| _version_ | 1818263052812812288 |
|---|---|
| author | SueAnn Costa Clemens Tania Azevedo Akira Homma |
| author_facet | SueAnn Costa Clemens Tania Azevedo Akira Homma |
| author_sort | SueAnn Costa Clemens |
| collection | DOAJ |
| description | Vaccination of infants with conjugated Haemophilus influenzae type b (Hib) vaccines has been proven to reduce Hib meningitis by 95% and pneumoniae by 20%. The routine use of Hib vaccine is facilitated by the introduction of combination vaccines into the EPI (Expanded Plan of Immunization). The objective of this study was to compare the immunogenicity and reactogenicity of an extemporaneously mixed DTPw/Hib (diphtheria-tetanus-whole cell pertussis) combination, using the technology of two Brazilian manufacturers, against a licensed DTPw/Hib European combination in 108 infants vaccinated at 2, 4 and 6 months according to the local national schedule. The Brazilian combination was highly immunogenic with Hib seroprotection rates (anti-PRP > 0.15 mg /ml of 98% after 2 doses and 100% after 3). Also for tetanus and pertussis the new Brazilian combination was as immunogenic as the European counterpart, except the diphtheria seroprotection rates and titers were lower. There was also no clinically relevant difference in reactogenicity. If these feasibility results are confirmed, the Brazilian DTPw/Hib combination should help to boost the uptake of Hib vaccination in Brazil. |
| first_indexed | 2024-12-12T19:12:53Z |
| format | Article |
| id | doaj.art-11cb376cb2704219829d1b7ef2ac773b |
| institution | Directory Open Access Journal |
| issn | 1678-9849 |
| language | English |
| last_indexed | 2024-12-12T19:12:53Z |
| publishDate | 2003-06-01 |
| publisher | Sociedade Brasileira de Medicina Tropical (SBMT) |
| record_format | Article |
| series | Revista da Sociedade Brasileira de Medicina Tropical |
| spelling | doaj.art-11cb376cb2704219829d1b7ef2ac773b2022-12-22T00:14:47ZengSociedade Brasileira de Medicina Tropical (SBMT)Revista da Sociedade Brasileira de Medicina Tropical1678-98492003-06-01363321330Feasibility study of the immunogenicity and safety of a novel DTPw/Hib (PRP-T) Brazilian combination compared to a licensed vaccine in healthy children at 2, 4, and 6 months of ageSueAnn Costa Clemens0Tania Azevedo1Akira Homma2Instituto Carlos ChagasUniversidade Federal do Rio de JaneiroFundação Oswaldo CruzVaccination of infants with conjugated Haemophilus influenzae type b (Hib) vaccines has been proven to reduce Hib meningitis by 95% and pneumoniae by 20%. The routine use of Hib vaccine is facilitated by the introduction of combination vaccines into the EPI (Expanded Plan of Immunization). The objective of this study was to compare the immunogenicity and reactogenicity of an extemporaneously mixed DTPw/Hib (diphtheria-tetanus-whole cell pertussis) combination, using the technology of two Brazilian manufacturers, against a licensed DTPw/Hib European combination in 108 infants vaccinated at 2, 4 and 6 months according to the local national schedule. The Brazilian combination was highly immunogenic with Hib seroprotection rates (anti-PRP > 0.15 mg /ml of 98% after 2 doses and 100% after 3). Also for tetanus and pertussis the new Brazilian combination was as immunogenic as the European counterpart, except the diphtheria seroprotection rates and titers were lower. There was also no clinically relevant difference in reactogenicity. If these feasibility results are confirmed, the Brazilian DTPw/Hib combination should help to boost the uptake of Hib vaccination in Brazil.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822003000300002&tlng=enCombination vaccinesDTPw/HibBrazilian vaccines technology transfer |
| spellingShingle | SueAnn Costa Clemens Tania Azevedo Akira Homma Feasibility study of the immunogenicity and safety of a novel DTPw/Hib (PRP-T) Brazilian combination compared to a licensed vaccine in healthy children at 2, 4, and 6 months of age Revista da Sociedade Brasileira de Medicina Tropical Combination vaccines DTPw/Hib Brazilian vaccines technology transfer |
| title | Feasibility study of the immunogenicity and safety of a novel DTPw/Hib (PRP-T) Brazilian combination compared to a licensed vaccine in healthy children at 2, 4, and 6 months of age |
| title_full | Feasibility study of the immunogenicity and safety of a novel DTPw/Hib (PRP-T) Brazilian combination compared to a licensed vaccine in healthy children at 2, 4, and 6 months of age |
| title_fullStr | Feasibility study of the immunogenicity and safety of a novel DTPw/Hib (PRP-T) Brazilian combination compared to a licensed vaccine in healthy children at 2, 4, and 6 months of age |
| title_full_unstemmed | Feasibility study of the immunogenicity and safety of a novel DTPw/Hib (PRP-T) Brazilian combination compared to a licensed vaccine in healthy children at 2, 4, and 6 months of age |
| title_short | Feasibility study of the immunogenicity and safety of a novel DTPw/Hib (PRP-T) Brazilian combination compared to a licensed vaccine in healthy children at 2, 4, and 6 months of age |
| title_sort | feasibility study of the immunogenicity and safety of a novel dtpw hib prp t brazilian combination compared to a licensed vaccine in healthy children at 2 4 and 6 months of age |
| topic | Combination vaccines DTPw/Hib Brazilian vaccines technology transfer |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822003000300002&tlng=en |
| work_keys_str_mv | AT sueanncostaclemens feasibilitystudyoftheimmunogenicityandsafetyofanoveldtpwhibprptbraziliancombinationcomparedtoalicensedvaccineinhealthychildrenat24and6monthsofage AT taniaazevedo feasibilitystudyoftheimmunogenicityandsafetyofanoveldtpwhibprptbraziliancombinationcomparedtoalicensedvaccineinhealthychildrenat24and6monthsofage AT akirahomma feasibilitystudyoftheimmunogenicityandsafetyofanoveldtpwhibprptbraziliancombinationcomparedtoalicensedvaccineinhealthychildrenat24and6monthsofage |